Sunesis Pharmaceuticals Announces Advancement into 100mg Cohort of Phase 1b/2 Trial of Vecabrutinib in Patients with CLL and Other B-Cell Malignancies
January 02, 2019 07:00 ET
|
Sunesis Pharmaceuticals, Inc.
- 50 mg Cohort Completed - - Clinical Update Expected in the Second Quarter of 2019 - SOUTH SAN FRANCISCO, Calif., Jan. 02, 2019 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS)...
Sunesis Pharmaceuticals Announces Presentation of Preliminary Data from Phase 1b/2 Trial of Vecabrutinib in Patients with CLL and Other B-Cell Malignancies at ASH Annual Meeting
December 02, 2018 12:00 ET
|
Sunesis Pharmaceuticals, Inc.
SOUTH SAN FRANCISCO, Calif., Dec. 02, 2018 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today announced the presentation of results from the Company’s Phase 1b/2 clinical trial of...
Sunesis Pharmaceuticals to Provide Program Update for Non-Covalent BTK-Inhibitor Vecabrutinib at Analyst & Investor Event during ASH 2018
November 28, 2018 07:00 ET
|
Sunesis Pharmaceuticals, Inc.
SOUTH SAN FRANCISCO, Calif., Nov. 28, 2018 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today announced it will provide a program update for vecabrutinib, the Company’s oral,...
Sunesis Pharmaceuticals to Present at the 30th Annual Piper Jaffray Healthcare Conference
November 19, 2018 07:00 ET
|
Sunesis Pharmaceuticals, Inc.
SOUTH SAN FRANCISCO, Calif., Nov. 19, 2018 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today announced that Willie Quinn, Chief Financial Officer and Senior Vice President,...
Sunesis Pharmaceuticals Reports Third Quarter 2018 Financial Results and Recent Highlights
November 05, 2018 16:05 ET
|
Sunesis Pharmaceuticals, Inc.
Sunesis to Host Conference Call Today at 4:30 PM Eastern Time SOUTH SAN FRANCISCO, Calif., Nov. 05, 2018 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) today reported financial...
Sunesis Pharmaceuticals Announces Presentations at 60th American Society of Hematology Annual Meeting
November 01, 2018 09:17 ET
|
Sunesis Pharmaceuticals, Inc.
SOUTH SAN FRANCISCO, Calif., Nov. 01, 2018 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) today announced two poster presentations and an oral presentation at the 60th American...
Sunesis Pharmaceuticals to Host Conference Call on November 5th to Discuss Third Quarter 2018 Financial Results and Recent Highlights
October 29, 2018 07:00 ET
|
Sunesis Pharmaceuticals, Inc.
SOUTH SAN FRANCISCO, Calif., Oct. 29, 2018 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) today announced that it will host a conference call on Monday, November 5th, 2018 at 4:30...
Sunesis Pharmaceuticals to Present at the 2018 Cantor Global Healthcare Conference
September 26, 2018 07:00 ET
|
Sunesis Pharmaceuticals, Inc.
SOUTH SAN FRANCISCO, Calif., Sept. 26, 2018 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) today announced that Willie Quinn, Chief Financial Officer and Senior Vice President,...
Sunesis Pharmaceuticals to Present at the Wells Fargo Securities 2018 Healthcare Conference
August 30, 2018 07:00 ET
|
Sunesis Pharmaceuticals, Inc.
SOUTH SAN FRANCISCO, Calif., Aug. 30, 2018 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) today announced that Willie Quinn, Chief Financial Officer and Senior Vice President,...
Sunesis Pharmaceuticals Reports Second Quarter 2018 Financial Results and Recent Highlights
August 07, 2018 16:05 ET
|
Sunesis Pharmaceuticals, Inc.
SOUTH SAN FRANCISCO, Calif., Aug. 07, 2018 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) today reported financial results for the quarter ended June 30, 2018. Loss from operations...